Combination of adoptive cell transfer and antibody injection can eradicate established tumors in mice--an in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb-

Immunopharmacol Immunotoxicol. 2010 Jun;32(2):238-45. doi: 10.3109/08923970903222355.

Abstract

Boosting an effective immune response against established tumors remains a difficult challenge. This study shows the combination of 1) adoptive cell transfer using CD25 depleted splenocytes co-cultured with irradiated tumor cells, and 2) antibody injection therapy using CTLA4 blockade, the elimination of Treg and OX40, which together could eradicate an established MethA tumor in over 50% of the BALB/c mice. Each element of the protocol was shown to be necessary, as elimination of any factor except anti-CD25 antibody injection failed to eradicate the tumor.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD / immunology*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • CTLA-4 Antigen
  • Combined Modality Therapy
  • Immunotherapy, Adoptive / methods*
  • Interleukin-2 Receptor alpha Subunit / immunology*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms, Experimental / drug therapy*
  • Neoplasms, Experimental / immunology
  • Receptors, OX40 / immunology*
  • Spleen / cytology
  • Spleen / drug effects
  • Spleen / immunology
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antineoplastic Agents
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • Interleukin-2 Receptor alpha Subunit
  • Receptors, OX40
  • Tnfrsf4 protein, mouse